Lexeo Therapeutics Inc. (NASDAQ: LXEO) started the day on Wednesday, with a price decrease of -17.00% at $8.27, before settling in for the price of $9.97 at the close. Taking a more long-term approach, LXEO posted a 52-week range of $7.86-$22.33.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of 19.69% over the last 5 years. Nevertheless, stock’s Earnings Per Share (EPS) this year is 77.69%. This publicly-traded company’s shares outstanding now amounts to $26.65 million, simultaneously with a float of $22.31 million. The organization now has a market capitalization sitting at $273.58 million. At the time of writing, stock’s 50-day Moving Average stood at $9.90, while the 200-day Moving Average is $13.42.
Lexeo Therapeutics Inc. (LXEO) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Lexeo Therapeutics Inc.’s current insider ownership accounts for 32.52%, in contrast to 66.10% institutional ownership. According to the most recent insider trade that took place on Oct 10 ’24, this organization’s Chief Executive Officer sold 5,000 shares at the rate of 8.10, making the entire transaction reach 40,496 in total value, affecting insider ownership by 120,695. Preceding that transaction, on Sep 10 ’24, Company’s Chief Executive Officer sold 5,000 for 10.65, making the whole transaction’s value amount to 53,274. This particular insider is now the holder of 120,695 in total.
Lexeo Therapeutics Inc. (LXEO) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.68 per share during the current fiscal year.
Lexeo Therapeutics Inc.’s EPS increase for this current 12-month fiscal period is 77.69% and is forecasted to reach -2.77 in the upcoming year.
Lexeo Therapeutics Inc. (NASDAQ: LXEO) Trading Performance Indicators
Let’s observe the current performance indicators for Lexeo Therapeutics Inc. (LXEO). It’s Quick Ratio in the last reported quarter now stands at 9.38. The Stock has managed to achieve an average true range (ATR) of 0.77.
In the same vein, LXEO’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.71, a figure that is expected to reach -0.68 in the next quarter, and analysts are predicting that it will be -2.77 at the market close of one year from today.
Technical Analysis of Lexeo Therapeutics Inc. (LXEO)
If we take a close look at the recent performances of Lexeo Therapeutics Inc. (NASDAQ: LXEO), its last 5-days Average volume was 0.38 million that shows progress from its year to date volume of 0.22 million. During the previous 9 days, stock’s Stochastic %D was recorded 30.42% While, its Average True Range was 0.81.
Raw Stochastic average of Lexeo Therapeutics Inc. (LXEO) in the period of the previous 100 days is set at 3.57%, which indicates a major fall in contrast to 12.08% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 133.65% that was higher than 97.96% volatility it exhibited in the past 100-days period.
